Delving into the Latest Updates on Organon Teknika Corp. LLC with Synapse

Overview

Title: First administration to man of Org 25435, a new intravenous anaesthetic.
Protocol: 12.4.104
Clinical Phase: Phase I
Study Site:
Phase I Clinical Trials Unit Ltd Old Convent of Notre Dame 119 Looseleigh Lane Plymouth PL6 5HH United Kingdom
Objectives: To assess the safety, tolerability, preliminary pharmacokinetics and efficacy of Org 25435 as an intravenous anaesthetic.
Study Design: Sequential study of an intravenous anaesthetic in young healthy males, at up to eight dose levels.
Study Drug: Org 25435, a water soluble intravenous anaesthetic.
Subjects: Up to 47 healthy male volunteers, aged 18-40 years.
Evaluations: Tolerability, adverse events, EEG effects, cardiovascular effects, electrocardiogram (ECG), excitatory phenomena, respiratory effects, laboratory safety blood analyses, pharmacodynamic and pharmacokinetic measurements.

Start Date01 Jan 2000

Sponsor / Collaborator

University of Plymouth

[+2]

100 Clinical Results associated with Organon Teknika Corp. LLC

Login to view more data

0 Patents (Medical) associated with Organon Teknika Corp. LLC

Login to view more data

10

Literatures (Medical) associated with Organon Teknika Corp. LLC

01 Feb 1997·Clinical ChemistryQ1 · MEDICINE

Fluid elements—a concept for automation of diagnostic tests

Q1 · MEDICINE

Article

Author: Pelssers, Eduard ; Van Velthoven, Thea ; Kaelen, Erik ; Van Damme, Henk

AbstractConstructs consisting of a channel, a membrane, and an absorber are designed for autonomously carrying out various liquid-handling functions of analytical tests. These so-called fluid elements can be used to set up various circuits for conducting several kinds of analytical tests. To demonstrate the feasibility of this concept, we constructed such a circuit and used it to perform, with two handling steps, an ELISA of hepatitis B surface antigen. The detection limit of the assay was comparable with those of state-of-the-art ELISAs for screening blood, and results could be obtained within a total test time of 20 min. We anticipate that this concept of automation may also serve as a basis for new, highly simplified immunoanalyzers.

01 Nov 1993·AIDSQ2 · MEDICINE

Qualitative and quantitative detection of HIV-1 RNA by nucleic acid sequence-based amplification

Q2 · MEDICINE

Article

Author: Goudsmit, Jaap ; Kievits, Tim ; Van Gemen, Bob ; Huisman, Han G. ; Lens, Peter ; Jurriaans, Suzanne ; Nara, Peter

AIMTo develop a method to detect HIV-1 viral RNA by amplifying a specific nucleic acid sequence.METHODThe nucleic acid sequence-based amplification (NASBA) method uses the simultaneous activity of avian myeloblastosis virus reverse transcriptase, T7 RNA polymerase and RNase H to amplify a specific nucleic acid target sequence.VALIDATIONAn in vitro cultured HIV-1 stock solution was used to validate the NASBA method and determine the variation in RNA measurement.CONCLUSIONAlthough NASBA is theoretically capable of specific amplification of RNA or DNA, it is most suitable for amplification of RNA, and therefore for detection of HIV-1 viral RNA.

Combined quantitation and genotyping of hepatitis C virus RNA using NASBA

Author: Van Deursen, P. ; Lens, P. ; Damen, M. ; Sillekens, P. ; Cuypers, T. ; Frantzen, I. ; Ehren, R. ; Boele, S. ; Melsert, R.

Hepatitis C virus (HCV) is known for its propensity to cause chronic hepatitis.At present, interferon α (IFN-α) is the only established treatment for chronic HCV infection.For monitoring antiviral therapy several methods are currently used including a one-tube method for direct quantification of HCV RNA in plasma or serum based on nucleic acid sequence-based amplification (NASBA) technol.Here we describe the basic principles of NASBA and it use in detecting HCV RNA.We found that NASBA-based HCV assays offer a complete system for direct detection of virus, quantitation of viral load and typing of the most predominant genotypes.We conclude that combined quantitation and genotyping can be performed on one and the same amplification reaction, providing a useful tool for prediction and monitoring of response to antiviral drug therapy.

100 Deals associated with Organon Teknika Corp. LLC

Login to view more data

100 Translational Medicine associated with Organon Teknika Corp. LLC

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 23 Dec 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Other

2

Login to view more data